Although their downregulation could be simply a bystander event during pancreatic cancer development, our findings revealed that the upregulations of ATF4, TXNIP, and REDD1 were concomitant with the therapeutic benefits of GW3965. The gene discussed is TXNIP; the disease is familial pancreatic carcinoma.